
Founded in 2011, Alopexx is a science-driven Investment, Management and Development Company. We invest in novel health care technologies at all stages of development. We have a large, experienced team with expertise at all stages of product development.
We work together with entrepreneurs, investors, scientists and corporate partners to develop breakthrough technologies that improve patients’ lives. Our portfolio companies are listed below
Company Highlights
January, 2019
Alopexx Vaccine Announces Licensing Agreement with Merck Animal Health
April, 2018
Alopexx Pharmaceuticals’ F598 Monoclonal Antibody Binds to poly-N-acetylglucosamine (PNAG) on Microbial Surfaces Offering Potential Protective Immunity Against Multiple Pathogens
October, 2017
Alopexx completes first-in-man trial of its novel, broad- spectrum anti-microbial vaccine
See More Highlights »